透景生命公告，第三季度营收为9855.3万元，同比下降6.36%；净利润为301.57万元，同比下降 83.02%。前三季度营收为2.58亿元，同比下降19.73%；净利润为577.49万元，同比下降76.33%。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥98,552,951.54, a decrease of 6.36% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥3,015,658.87, down 83.02% year-on-year[4]. - The basic earnings per share decreased to ¥0.0186, reflecting an 83.00% decline compared to the previous year[4]. - Total revenue for the current period was ¥257,613,224.35, a decrease of approximately 19.7% compared to ¥320,918,983.86 in the previous period[24]. - In Q3 2025, the company's net profit was CNY 2,839,782.28, a significant decrease from CNY 19,767,610.53 in the same period last year, representing a decline of approximately 85.6%[25]. - The total comprehensive income for the period was CNY 3,060,471.70, down from CNY 19,996,771.99, indicating a decrease of approximately 84.7%[25]. - The company reported a total profit of CNY 3,117,944.68, down from CNY 22,531,669.75, reflecting a decrease of approximately 86.2%[25]. Assets and Liabilities - Total assets increased by 14.40% to ¥2,000,760,511.63 compared to the end of the previous year[4]. - Total assets rose to ¥2,000,760,511.63 from ¥1,748,986,409.73, marking an increase of approximately 14.4%[23]. - Total liabilities increased to ¥472,836,217.37 from ¥230,944,723.47, reflecting a significant rise of about 105.5%[22]. - Non-current liabilities grew to ¥386,085,378.67 from ¥99,787,476.32, indicating an increase of approximately 287.5%[22]. - The company's equity attributable to shareholders decreased to ¥1,471,072,927.99 from ¥1,507,492,840.59, a decline of about 2.4%[23]. Cash Flow - The company reported a net cash flow from operating activities of ¥103,104,566.22, a decrease of 7.30% year-to-date[11]. - The company reported a net cash flow from operating activities of CNY 103,104,566.22, compared to CNY 111,225,112.81 in the previous year, reflecting a decline of approximately 7.5%[27]. - Investment activities resulted in a net cash outflow of CNY 222,966,441.49, slightly improved from a net outflow of CNY 242,800,556.74 in the prior year[27]. - The company raised CNY 271,863,103.00 through borrowings, a significant increase from CNY 76,046,404.55 in the previous year, marking an increase of approximately 257.5%[27]. - Cash and cash equivalents increased to ¥395,652,885.52 from ¥308,738,859.31, representing a growth of about 28.1%[21]. - The company's cash and cash equivalents at the end of the period increased to CNY 390,472,485.52 from CNY 269,290,121.50, representing an increase of about 45.0%[27]. Borrowings and Financing - The company experienced a significant increase in short-term borrowings, rising by 84.76% to ¥11,073,759.16 due to the consolidation of subsidiary short-term loans[9]. - The company's short-term borrowings increased to ¥11,073,759.16 from ¥5,993,515.26, representing an increase of approximately 84.7%[22]. - The company’s cash flow from financing activities increased by 911.24% to ¥213,108,193.15, primarily due to cash received from acquisition financing[11]. Shareholder Information - Major shareholders include Ying Er Yao with 20.15% and Lingfei Group with 7.40% of shares[14]. - The company repurchased a total of 737,000 shares, accounting for 0.45% of the total share capital, with a total payment of RMB 20,026,948.40[18]. - The highest repurchase price during the buyback was RMB 29.34 per share, while the lowest was RMB 23.89 per share[18]. - The company has a plan to use the repurchased shares for employee stock ownership plans[18]. - The company has a total of 2,683,150 shares held in a repurchase special account as of the reporting period[14]. - The company has not disclosed any other related party relationships among the top 10 shareholders[17]. - The company has not reported any changes in the lending of shares by major shareholders due to margin trading[15]. Mergers and Acquisitions - The company plans to acquire 82.00% of Wuhan Kanglu Biotechnology Co., Ltd. in a transaction totaling RMB 328 million, to be completed in three phases from 2025 to 2027[19][20]. - As of the reporting period, the company has completed the share transfer for 2025, and Kanglu Biotechnology has been integrated into the company's consolidated financial statements[20]. - The company’s goodwill reached ¥188,489,219.38, attributed to mergers and acquisitions[8]. Operating Costs and Expenses - Total operating costs decreased to ¥237,122,494.65 from ¥287,293,766.22, reflecting a reduction of about 17.5%[24]. - Research and development expenses were ¥39,990,947.86, down from ¥49,460,725.22, indicating a decrease of approximately 19.9%[24]. - The company’s investment income showed a significant decline of 501.01%, resulting in a loss of ¥6,049,434.19[10]. - The company reported a net investment loss of ¥6,049,434.19 compared to a gain of ¥1,508,551.44 in the previous period[24]. - The company experienced a credit impairment loss of CNY -12,578,990.17, worsening from CNY -10,237,654.36 in the previous year[25].

上海透景生命科技股份有限公司 证券代码：300642 证券简称：透景生命 公告编号：2025-074 关于注销部分股票期权和回购注销部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 10 月 22 日，上海透景生命科技股份有限公司（以下简称"公司" 或"透景生命"）召开第四届董事会第十四次会议和第四届监事会第十一次会议， 分别审议并通过了《关于注销部分股票期权和回购注销部分限制性股票的议案》， 现将有关事项说明如下： 一、2023 年股票期权与限制性股票激励计划实施简述 1、2023 年 1 月 19 日，公司召开了第三届董事会第十五次会议，审议通过 了《关于公司<2023 年股票期权与限制性股票激励计划（草案）>及其摘要的议 案》、《关于公司<2023 年股票期权与限制性股票激励计划实施考核管理办法> 的议案》、《关于提请公司股东大会授权董事会办理公司 2023 年股票期权与限 制性股票激励计划有关事项的议案》等议案。独立董事对 2023 年股票期权与限 制性股票激励计划（以下简称"2023 年股权激励计划"或"2023 年 ...

关于回购注销部分激励对象已获授但尚未解除限售的 限制性股票减资通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日召开第四届董事会第十四次会议，审议并通过了《关于注销部分股票期权和回 购注销部分限制性股票的议案》。根据公司《2023 年股票期权与限制性股票激 励计划（草案）》的规定，公司将对已授予但不再符合解除限售条件的 12,000 股限制性股票进行回购注销。具体情况请详见公司于同期在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于注销部分股票期权和回购注销部分 限制性股票的公告》（公告编号：2025-074）。回购完毕后，公司将向中国证券 登记结算有限责任公司深圳分公司申请该部分股票的注销。注销完成后，公司股 份总额将由 162,556,041 股减少至 162,544,041 股，注册资本由 162,556,041 元减少至 162,544,041 元。 公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华人民共 和国公司 ...

证券简称：透景生命 证券代码：300642 上海荣正企业咨询服务（集团）股份有限公司 关于 上海透景生命科技股份有限公司 注销部分股票期权及回购注销部分限制性股票 相关事项 之 一、释义 3 1. 上市公司、公司、透景生命：指上海透景生命科技股份有限公司。 2. 2023 年股权激励计划：指《上海透景生命科技股份有限公司 2023 年股票期 权与限制性股票激励计划（草案）》。 3. 股票期权、期权：指公司授予激励对象在未来一定期限内以预先确定的价格 和条件购买本公司一定数量股票的权利。 4. 限制性股票：指公司根据本激励计划规定的条件和价格，授予激励对象一定 数量的公司股票，该等股票设置一定期限的限售期，在达到本激励计划规定 的解除限售条件后，方可解除限售流通。 5. 激励对象：指按照本激励计划规定，获得股票期权/限制性股票的公司（含 分公司、子公司）董事、高级管理人员、中层管理人员及核心技术（业务） 骨干。 6. 授权日、授予日：指公司向激励对象授予权益的日期，授权日/授予日必须 为交易日。 7. 等待期：指股票期权授权之日至股票期权可行权日之间的时间段。 8. 行权：指激励对象按照激励计划设定的条件购买标 ...

2023 年股票期权与限制性股票激励计划相关事项的法律意见 致：上海透景生命科技股份有限公司 上海市广发律师事务所（以下简称"本所"）接受上海透景生命科技股份有 限公司（以下简称"公司"）的委托，作为其 2023 年股票期权与限制性股票激励 计划（以下简称"2023 年股权激励计划""本次股权激励计划"）的专项法律顾 问，就本次股权激励计划所涉注销部分股票期权、回购注销部分限制性股票（以 下简称"本次注销/回购注销"）事项，根据《中华人民共和国证券法》（以下简 称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、中国证 券监督管理委员会（以下简称"中国证监会"）颁布的《上市公司股权激励管理 办法》（以下简称"《管理办法》"）等法律、法规、规范性文件以及《上海透景 生命科技股份有限公司章程》（以下简称"《公司章程》"）、《上海透景生命科技 股份有限公司 2023 年股票期权与限制性股票激励计划》（以下简称"《2023 年 股权激励计划》"）的有关规定，并按照律师行业公认的业务标准、道德规范和勤 勉尽责精神出具本法律意见书。 本所依据本法律意见书出具日以前已发生或存在的事实和我国现行法律、法 ...

Core Insights - The precision medicine sector experienced a 1.97% increase on October 15, with Tsinghua Life leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Tsinghua Life (300642) closed at 25.85, up 10.38% with a trading volume of 294,900 shares and a transaction value of 756 million [1] - Beilu Pharmaceutical (300016) closed at 8.77, up 4.78% with a trading volume of 251,800 shares and a transaction value of 26.61 million [1] - Zoli Pharmaceutical (300181) closed at 19.07, up 4.21% with a trading volume of 283,300 shares and a transaction value of 534 million [1] - WuXi AppTec (603259) closed at 99.46, up 3.69% with a trading volume of 421,800 shares and a transaction value of 4.123 billion [1] - Qianhong Pharmaceutical (002550) closed at 9.08, up 3.42% with a trading volume of 301,300 shares and a transaction value of 271 million [1] Capital Flow - The precision medicine sector saw a net inflow of 339 million from institutional investors, while retail investors experienced a net outflow of 18.88 million [2][3] - Major stocks like Zoli Pharmaceutical and Anke Bio (300009) had significant net inflows from institutional investors, with 76.71 million and 54.19 million respectively [3]

Market Overview - The medical device sector increased by 0.72% on October 15, with TuoJing Life leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Top Performers - TuoJing Life (300642) closed at 25.85, up 10.38% with a trading volume of 294,900 shares and a transaction value of 756 million [1] - JiMin Health (603222) closed at 10.97, up 10.03% with a trading volume of 353,400 shares [1] - MaiLanDe (688273) closed at 43.90, up 9.75% with a trading volume of 47,500 shares [1] - KeFu Medical (301087) closed at 43.10, up 7.86% with a trading volume of 72,700 shares [1] - Rejing Bio (688068) closed at 170.79, up 6.96% with a trading volume of 34,700 shares [1] Underperformers - JinHao Medical (920925) closed at 34.05, down 3.81% with a trading volume of 15,400 shares [2] - DaBo Medical (002901) closed at 55.52, down 2.94% with a trading volume of 29,400 shares [2] - HuaDa ZhiZao (688114) closed at 68.57, down 2.93% with a trading volume of 52,400 shares [2] Capital Flow - The medical device sector saw a net inflow of 500 million in main funds, while retail investors experienced a net outflow of 214 million [2][3] - Major stocks like SaiNuo Medical (688108) had a net inflow of 129 million from main funds, while JiMin Health (603222) saw a net outflow of 471 million from retail investors [3]

（文章来源：证券日报） 证券日报网讯 10月10日晚间，透景生命发布公告称，2025年8月28日，公司首次通过股票回购专用账户 以集中竞价交易方式实施回购股份。截至本公告披露日，公司本次回购股份已实施完毕，实际回购时间 为2025年8月28日至2025年9月30日，期间公司通过回购专用证券账户以集中竞价交易方式实施回购股份 合计737，000股，占公司当前总股本的0.45%。 ...

格隆汇10月10日丨透景生命(300642.SZ)公布，截至本公告披露日，公司本次回购股份已实施完毕，实 际回购时间为2025年8月28日至2025年9月30日，期间公司通过回购专用证券账户以集中竞价交易方式实 施回购股份合计737,000股，占公司当前总股本的0.45%，本次回购股份成交的最高价格为29.34元/股， 成交的最低价格为23.89元/股，支付的总金额为人民币20,026,948.40元（不含交易费用）。本次回购符 合公司既定的回购方案以及相关法律法规的要求。 ...